We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+12.09%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$823M
AUM Growth
-$2.43M
Cap. Flow
-$27.4M
Cap. Flow %
-3.33%
Top 10 Hldgs %
55.08%
Holding
68
New
13
Increased
12
Reduced
21
Closed
14

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$14.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$13.6M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.6M
4
CORI
Corium International, Inc.
CORI
+$9.81M
5
PETX
Aratana Therapeutics, Inc.
PETX
+$9.16M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$19.9M
2
ADXS
Advaxis Inc
ADXS
+$12.4M
3
MDCO
Medicines Co
MDCO
+$10.5M
4
DRRX
DURECT Corp
DRRX
+$8.93M
5
SPNE
SeaSpine Holdings Corporation Common Stock
SPNE
+$8.63M

Sector Composition

Rank Sector Weight
1 Healthcare 74.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$77.2M 9.38%
1,000,000
– –
HRTX icon
2
Heron Therapeutics
HRTX
$89.1M
$61.2M 7.43%
4,418,359
-529,044
-11% -$7.66M
TVTX icon
3
Travere Therapeutics
TVTX
$5.24B
$55.5M 6.74%
2,862,178
-30,000
-1% -$544K
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$48.2M 5.86%
4,060,847
-1,603,372
-28% -$19.9M
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$45.6M 5.54%
4,133,464
-261,000
-6% -$2.62M
PETX
6
DELISTED
Aratana Therapeutics, Inc.
PETX
$37.5M 4.55%
5,184,942
+1,489,500
+40% +$9.16M
LJPC
7
DELISTED
La Jolla Pharmaceutical Company
LJPC
$37.4M 4.55%
1,257,887
+475,000
+61% +$13.6M
CORI
8
DELISTED
Corium International, Inc.
CORI
$33.1M 4.02%
4,436,726
+1,649,605
+59% +$9.81M
RXDX
9
DELISTED
Ignyta, Inc.
RXDX
$30.4M 3.7%
2,941,247
+303,901
+12% +$2.47M
ANGO icon
10
AngioDynamics
ANGO
$549M
$27.3M 3.31%
1,683,252
+217,800
+15% +$3.44M
ENDP
11
CALL
DELISTED
Endo International plc
ENDP
$22.3M 2.71%
2,000,000
– –
SCTL
12
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$21.8M 2.65%
3,456,596
– –
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
$20.5M 2.49%
2,871,928
-109,778
-4% -$507K
CPRX
14
DELISTED
Catalyst Pharmaceutical
CPRX
$20.3M 2.46%
7,350,000
-850,000
-10% -$1.77M
NVLN
15
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$18M 2.18%
1,948,554
– –
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.19B
$16.7M 2.03%
2,276,359
-232,700
-9% -$1.48M
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
$16.3M 1.98%
+310,000
New +$14.4M
ATRS
18
DELISTED
Antares Pharma, Inc.
ATRS
$15.5M 1.88%
4,803,528
-2,838,678
-37% -$8.05M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$35.6B
$14.5M 1.76%
+181,200
New +$11.6M
BDSI
20
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$14.3M 1.74%
5,122,094
-276,700
-5% -$584K
ENDP
21
DELISTED
Endo International plc
ENDP
$13.9M 1.69%
1,246,923
-636,815
-34% -$7.48M
TLGT
22
DELISTED
Teligent, Inc
TLGT
$13.4M 1.63%
146,745
-46,426
-24% -$3.95M
GILD icon
23
CALL
Gilead Sciences
GILD
$165B
$12.7M 1.55%
+180,000
New +$12M
VCYT icon
24
Veracyte
VCYT
$4.7B
$12.1M 1.46%
1,446,866
-201,700
-12% -$1.65M
HZNP
25
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.9M 1.44%
1,000,000
– –
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Broadfin Capital held 68 positions worth $823M, down 0.29% from $826M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $27.4M in Q2 2017, closing 14 positions and reducing 21 holdings. Its most notable exit was Advaxis Inc, an estimated $12.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 77% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Aerie Pharmaceuticals worth $16.3M.

  • Broadfin Capital's largest Q2 2017 buy was Aerie Pharmaceuticals: 310,000 shares worth $16.3M.
  • Broadfin Capital added most to La Jolla Pharmaceutical Company in Q2 2017, an estimated $13.6M increase.
  • Broadfin Capital's biggest Q2 2017 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $19.9M.
  • Broadfin Capital fully exited Advaxis Inc in Q2 2017, selling an estimated $12.4M.
  • Broadfin Capital's ten largest holdings make up 55% of its $823M portfolio in Q2 2017.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2017.
  • Broadfin Capital's portfolio value fell 0.29% quarter-over-quarter to $823M.

Based on Broadfin Capital's 13F filing for Q2 2017, filed 14 Aug 2017.